Trial Profile
A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Compare the Pharmacokinetic Profiles of Three Different Strengths of ASP015K Extended Release Formulation With ASP015K Immediate Release Formulation and to Evaluate Food Effect on Extended Release Strengths in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peficitinib (Primary)
- Indications Plaque psoriasis; Rheumatoid arthritis; Transplant rejection
- Focus Pharmacokinetics
- 24 Sep 2012 New trial record